This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Eosinophilic Esophagitis
  • /
  • A Clinical Severity Index for Eosinophilic Esophag...

A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions

Read time: 1 mins
Last updated:1st Jul 2022
Availability: Free full text
Status: Live
A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions - The American Gastroenterological Association (AGA)

Background & Aims:
Disease activity and severity of eosinophilic esophagitis (EoE) dictate therapeutic options and management, but the decision-making process for determining severity varies among practitioners. To reduce variability in practice patterns and help clinicians monitor the clinical course of the disease in an office setting, we aimed to create an international consensus severity scoring index for EoE.

Methods: A multidisciplinary international group of adult and pediatric EoE researchers and clinicians, as well as non-EoE allergy immunology and gastroenterology experts, formed 3 teams to review the existing literature on histology, endoscopy, and symptoms of EoE in the context of progression and severity. A steering committee convened a 1-day virtual meeting to reach consensus on each team’s opinion on salient features of severity across key clinicopathologic domains and distill features that would allow providers to categorize disease severity.

Results: Symptom features and complications and inflammatory and fibrostenotic features on both endoscopic and histologic examination were collated into a simplified scoring system—the Index of Severity for Eosinophilic Esophagitis (I-SEE)—that can be completed at routine clinic visits to assess disease severity using a point scale of 0–6 for mild, 7–14 for moderate, and ≥15 for severe EoE.

Conclusions: A multidisciplinary team of experts iteratively created a clinically usable EoE severity scoring system denominated “I-SEE” to guide practitioners in EoE management by standardizing disease components reflecting disease severity beyond eosinophil counts. I-SEE should be validated and refined using data from future clinical trials and routine clinical practice to increase its utilization and functionality.

Read full Guideline